A. Rapkin

Publications125
h-index36
Citations4,589
Highly Influential Citations196
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Freeman
  • 251 Publications, 12,002 Citations
  • D. Rubinow
  • 399 Publications, 20,394 Citations
  • S. Bergeron
  • 154 Publications, 4,599 Citations
  • U. Halbreich
  • 282 Publications, 11,456 Citations
  • Publications
  • Influence
Efficacy of a New Low-Dose Oral Contraceptive With Drospirenone in Premenstrual Dysphoric Disorder
Objective: To compare the efficacy of a new low-dose oral contraceptive pill (OCP) formulation with placebo in reducing symptoms of premenstrual dysphoric disorder. Methods: This multicenter,… Expand
  • 264
  • 18
  • PDF
Towards a consensus on diagnostic criteria, measurement and trial design of the premenstrual disorders: the ISPMD Montreal consensus
Premenstrual disorders (PMD) are characterised by a cluster of somatic and psychological symptoms of varying severity that occur during the luteal phase of the menstrual cycle and resolve during… Expand
  • 156
  • 18
Clinical diagnostic criteria for premenstrual syndrome and guidelines for their quantification for research studies
Premenstrual syndrome (PMS) encompasses a variety of symptoms appearing during the luteal phase of the menstrual cycle. Although PMS is widely recognized, the etiology remains unclear and it lacks… Expand
  • 124
  • 10
  • PDF
Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness
  • A. Rapkin, S. Winer
  • Medicine
  • Expert review of pharmacoeconomics & outcomes…
  • 1 April 2009
Premenstrual symptoms are distressing for up to 20% of reproductive-aged women and are associated with impairment in interpersonal or workplace functioning for at least 3–8%. Typical symptoms of… Expand
  • 120
  • 10
Progesterone Metabolite Allopregnanolone in Women With Premenstrual Syndrome
Objective To evaluate the anxiolytic 3α-5α-reduced progesterone metabolite allopregnanolone in the luteal phase of the menstrual cycle in women with premenstrual syndrome (PMS) and controls. Methods… Expand
  • 297
  • 9
  • PDF
A review of treatment of premenstrual syndrome & premenstrual dysphoric disorder
  • A. Rapkin
  • Medicine
  • Psychoneuroendocrinology
  • 1 August 2003
Severe premenstrual syndrome (PMS) and, more recently, premenstrual dysphoric disorder (PMDD) have been studied extensively over the last 20 years. The defining criteria for diagnosis of the… Expand
  • 172
  • 9
  • PDF
Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder.
Premenstrual dysphoric disorder (PMDD) is a severe form of premenstrual syndrome (PMS). This is the first trial of a unique oral contraceptive containing a combination of drospirenone (DRSP, 3 mg)… Expand
  • 149
  • 8
Unwanted sexual experiences among middle and high school youth.
Of the 1197 middle and high schoo students who participated anonymously in a health survey, 15% reported they had had a past unwanted sexual experience. Females were more likely than males and older… Expand
  • 137
  • 7
ISPMD consensus on the management of premenstrual disorders
The second consensus meeting of the International Society for Premenstrual Disorders (ISPMD) took place in London during March 2011. The primary goal was to evaluate the published evidence and… Expand
  • 91
  • 7
Relationships among self-rated tanner staging, hormones, and psychosocial factors in healthy female adolescents.
STUDY OBJECTIVE Females are more likely than males to suffer from various mood and pain disorders. However, this female predominance does not appear to develop until puberty. The purpose of the… Expand
  • 43
  • 6